Please login to the form below

urothelial carcinoma

This page shows the latest urothelial carcinoma news and features for those working in and with pharma, biotech and healthcare.

BMS presses go on Nektar combo pivotal trials, despite data debate

The phase I/II PIVOT trial met the criteria needed to advance PD-1 inhibitor Opdivo (nivolumab) and CD122-biased agonist NKTR0214 into pivotal trials in melanoma, renal cell carcinoma and ... Nektar and BMS also reported initial stage 1 data in

Latest news

Keytruda gains NICE clearance in first line bladder cancer

Cost effectiveness watchdog NICE issued a Final Appraisal Determination (FAD) on Friday, recommending MSD’s treatment within the cancer drugs fund (CDF) for untreated locally advanced or metastatic urothelial carcinoma in ... Pembrolizumab is already
Another Tecentriq win for Roche as Avastin combo boosts survival

Tecentriq is currently approved for previously-treated NSCLC patients and also as a second-line therapy for metastatic urothelial carcinoma, a form of bladder cancer.
NICE says OK to Keytruda for bladder cancer via the CDF

metastatic urothelial carcinoma in adults who have had platinum-containing chemotherapy. ... Louise Houson, UK managing director for MSD, said: “MSD is really pleased that NICE has recommended pembrolizumab for eligible patients with advanced
MSD’s Keytruda wins bladder cancer indication in Japan

The pharma giant’s blockbuster has gained a new indication to treat patients with previously treated urothelial carcinoma (UC) that is unresectable with radical surgery and whose disease has progressed following ... chemotherapy. Dr Roy Baynes, senior
Merck and Pfizer’s PD-L1 drug Bavencio flunks phase III trial

The drug is already approved as a treatment for rare cancer Merkel cell carcinoma and as a second-line therapy for bladder cancer (metastatic urothelial carcinoma), but Pfizer and Merck are

More from news
Approximately 2 fully matching, plus 22 partially matching documents found.

Latest Intelligence

Europe vs the US: New drug product approvals

Tecentriq (for the treatment of urothelial carcinoma, only approved in the US), and Venclexta (for the treatment of chronic lymphocytic leukaemia, approved in the EU and US).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Home-based Senior Project Manager – Independent Med Ed: Salary TBC

Business Director: Competitive Salary Offered

Account Manager / Account Director: Competative

Client Services Director – Medical Education Agency – North West...: Salary TBC

Senior Account Manager, Rare Diseases – Medical Communications, ...: Excellent package

Global Business Development Director – Health Education: excellent commission

Engagement Expert, Healthcare Brand Communications, London: Excellent package

Senior Account Manager: Competitive Salary Offered

Account Manager / Senior Account Manager: 35, 000-40, 000

Associate Director: £75, 000-90, 000

Editorial Assistant Medical Education Agency: £25, 000 - £26, 000

Account Director, Healthcare Marketing Agency: Salary TBC

Senior Medical Writer: Salary TBC

Account Director, Medical Education: Salary TBC

Medical Writer: Salary TBC

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

Senior Account Director development role to Business Director, H...: Excellent package

Account Director: Competitive Salary Offered

Account Director – Health Policy – Global Agency: Salary TBC

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Account Director – Healthcare Marketing – Berks: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?: Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement: Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape: Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....